Accordingly, tumours that attained pCR had higher predicted neoantigen burdens (median neoantigens pCR: 28, residual disease: 17, P = 0.009; Fig. 2c), and after stratification, this was observed only in HER2− tumours (P = 0.004; Extended Data Fig. 4d). This evidence concerns the gene ERBB2 and neoplasm.